Kura Oncology KURA Commercialization Services — Contract With Customer Liability Noncurrent
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's commercialization services — contract with customer liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kura Oncology's commercialization services — contract with customer liability noncurrent?
- Kura Oncology (KURA) reported commercialization services — contract with customer liability noncurrent of $273.7M in Q1 2026.
- What does commercialization services — contract with customer liability noncurrent mean?
- Represents the portion of deferred revenue from commercialization services that is expected to be recognized as revenue beyond the next twelve months. This reflects long-term contractual obligations where payment has been received or is due before the services are fully performed. It indicates the scale of multi-year commercial partnerships.